Related Experiment Video
Updated: May 10, 2026

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
OCT-based AI-assisted phenotyping of intermediate AMD in the prospective PINNACLE trial: PINNACLE Study Report 9
Sophie Riedl1, Julia Mai1, Marie Louise Enzendorfer2
1Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
This study characterizes intermediate age-related macular degeneration (iAMD) using optical coherence tomography (OCT). It reveals key morphological features and their distribution, aiding future clinical trial design and iAMD research.
Area of Science:
- Ophthalmology
- Medical Imaging
- Retinal Diseases
Background:
- Intermediate age-related macular degeneration (iAMD) progression is not fully understood.
- Large-scale prospective studies are needed for comprehensive characterization.
Purpose of the Study:
- To provide a detailed optical coherence tomography (OCT)-based morphological characterization of the PINNACLE intermediate age-related macular degeneration (iAMD) cohort.
- To analyze the prevalence, distribution, and intercorrelation of iAMD features.
Main Methods:
- Utilized expert grader readings and artificial intelligence (AI) for OCT image analysis.
- Quantified drusen, subretinal drusenoid deposits (SDD), hyperreflective foci (HRF), and outer retinal integrity (EZ, ONL).
- Assessed incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) and ellipsoid zone loss/choroidal hypertransmission (EZLHT).
Main Results:
- Drusen concentrated centrally; SDD predominantly in the superior perifoveal quadrant.
- Higher drusen volume correlated with HRF presence/volume but inversely with SDD.
- Outer retinal thinning (EZ, ONL) indicates photoreceptor compromise, especially with atrophy (iRORA, EZLHT).
Conclusions:
- Combined expert and AI OCT analysis on the largest prospective iAMD cohort.
- Morphological findings align with existing literature, offering substantial characterization.
- Data is valuable for interpreting longitudinal iAMD progression, refining trial criteria, and serving as a reference.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
